vs
赫克（HURC）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是赫克的1.4倍（$65.1M vs $45.5M）。MESA LABORATORIES INC净利率更高（5.6% vs -6.7%，领先12.3%）。MESA LABORATORIES INC同比增速更快（3.6% vs -15.3%）。MESA LABORATORIES INC自由现金流更多（$18.0M vs $3.6M）。过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 0.5%）
赫克公司是全球工业技术企业，主营数控（CNC）机床及配套控制软件的设计、生产与销售，产品涵盖各类加工中心、车削中心等，服务航空航天、汽车、能源、通用金属加工等领域客户，业务覆盖欧美及亚太市场。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
HURC vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.4倍
$45.5M
营收增速更快
MLAB
高出19.0%
-15.3%
净利率更高
MLAB
高出12.3%
-6.7%
自由现金流更多
MLAB
多$14.4M
$3.6M
两年增速更快
MLAB
近两年复合增速
0.5%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $45.5M | $65.1M |
| 净利润 | $-3.0M | $3.6M |
| 毛利率 | 17.0% | 64.2% |
| 营业利润率 | -7.6% | 12.2% |
| 净利率 | -6.7% | 5.6% |
| 营收同比 | -15.3% | 3.6% |
| 净利润同比 | -110.9% | 316.6% |
| 每股收益（稀释后） | $-0.47 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HURCMLAB
| Q4 25 | $45.5M | $65.1M | ||
| Q3 25 | $45.8M | $60.7M | ||
| Q2 25 | $40.9M | $59.5M | ||
| Q1 25 | $46.4M | $62.1M | ||
| Q4 24 | $53.7M | $62.8M | ||
| Q3 24 | $42.7M | $57.8M | ||
| Q2 24 | $45.2M | $58.2M | ||
| Q1 24 | $45.1M | $58.9M |
净利润HURCMLAB
| Q4 25 | $-3.0M | $3.6M | ||
| Q3 25 | $-3.7M | $2.5M | ||
| Q2 25 | $-4.1M | $4.7M | ||
| Q1 25 | $-4.3M | $-7.1M | ||
| Q4 24 | $-1.4M | $-1.7M | ||
| Q3 24 | $-9.6M | $3.4M | ||
| Q2 24 | $-3.9M | $3.4M | ||
| Q1 24 | $-1.6M | $-254.6M |
毛利率HURCMLAB
| Q4 25 | 17.0% | 64.2% | ||
| Q3 25 | 19.9% | 61.5% | ||
| Q2 25 | 19.2% | 62.0% | ||
| Q1 25 | 17.9% | 61.8% | ||
| Q4 24 | 22.7% | 63.3% | ||
| Q3 24 | 18.4% | 61.3% | ||
| Q2 24 | 17.8% | 64.0% | ||
| Q1 24 | 21.5% | 62.1% |
营业利润率HURCMLAB
| Q4 25 | -7.6% | 12.2% | ||
| Q3 25 | -3.6% | 7.8% | ||
| Q2 25 | -7.5% | 5.1% | ||
| Q1 25 | -4.5% | 2.4% | ||
| Q4 24 | -0.9% | 9.2% | ||
| Q3 24 | -5.9% | 6.1% | ||
| Q2 24 | -7.6% | 9.6% | ||
| Q1 24 | -4.0% | -460.6% |
净利率HURCMLAB
| Q4 25 | -6.7% | 5.6% | ||
| Q3 25 | -8.1% | 4.1% | ||
| Q2 25 | -9.9% | 8.0% | ||
| Q1 25 | -9.3% | -11.4% | ||
| Q4 24 | -2.7% | -2.7% | ||
| Q3 24 | -22.5% | 5.9% | ||
| Q2 24 | -8.7% | 5.8% | ||
| Q1 24 | -3.7% | -432.2% |
每股收益（稀释后）HURCMLAB
| Q4 25 | $-0.47 | $0.65 | ||
| Q3 25 | $-0.58 | $0.45 | ||
| Q2 25 | $-0.62 | $0.85 | ||
| Q1 25 | $-0.67 | $-1.30 | ||
| Q4 24 | $-0.23 | $-0.31 | ||
| Q3 24 | $-1.47 | $0.63 | ||
| Q2 24 | $-0.61 | $0.62 | ||
| Q1 24 | $-0.25 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $48.7M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $198.8M | $186.7M |
| 总资产 | $264.3M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资HURCMLAB
| Q4 25 | $48.7M | $29.0M | ||
| Q3 25 | $44.5M | $20.4M | ||
| Q2 25 | $43.8M | $21.3M | ||
| Q1 25 | $41.8M | $27.3M | ||
| Q4 24 | $33.3M | $27.3M | ||
| Q3 24 | $36.1M | $24.3M | ||
| Q2 24 | $37.5M | $28.5M | ||
| Q1 24 | $37.9M | $28.2M |
总债务HURCMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益HURCMLAB
| Q4 25 | $198.8M | $186.7M | ||
| Q3 25 | $203.7M | $178.5M | ||
| Q2 25 | $202.3M | $172.5M | ||
| Q1 25 | $198.1M | $159.8M | ||
| Q4 24 | $207.2M | $155.2M | ||
| Q3 24 | $206.6M | $161.5M | ||
| Q2 24 | $215.6M | $150.7M | ||
| Q1 24 | $224.6M | $145.4M |
总资产HURCMLAB
| Q4 25 | $264.3M | $434.8M | ||
| Q3 25 | $269.1M | $430.4M | ||
| Q2 25 | $262.5M | $435.7M | ||
| Q1 25 | $255.8M | $433.3M | ||
| Q4 24 | $268.6M | $433.3M | ||
| Q3 24 | $272.4M | $454.1M | ||
| Q2 24 | $280.8M | $440.4M | ||
| Q1 24 | $290.1M | $446.8M |
负债/权益比HURCMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.7M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $3.6M | $18.0M |
| 自由现金流率自由现金流/营收 | 8.0% | 27.7% |
| 资本支出强度资本支出/营收 | 0.1% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $16.7M | $37.9M |
8季度趋势，按日历期对齐
经营现金流HURCMLAB
| Q4 25 | $3.7M | $18.8M | ||
| Q3 25 | $2.5M | $8.2M | ||
| Q2 25 | $997.0K | $1.9M | ||
| Q1 25 | $10.3M | $12.7M | ||
| Q4 24 | $-1.2M | $18.1M | ||
| Q3 24 | $-622.0K | $5.3M | ||
| Q2 24 | $1.9M | $10.7M | ||
| Q1 24 | $-2.6M | $12.9M |
自由现金流HURCMLAB
| Q4 25 | $3.6M | $18.0M | ||
| Q3 25 | $2.1M | $7.1M | ||
| Q2 25 | $689.0K | $884.0K | ||
| Q1 25 | $10.2M | $11.9M | ||
| Q4 24 | $-1.7M | $17.3M | ||
| Q3 24 | $-841.0K | $3.5M | ||
| Q2 24 | $1.7M | $9.9M | ||
| Q1 24 | $-3.0M | $12.3M |
自由现金流率HURCMLAB
| Q4 25 | 8.0% | 27.7% | ||
| Q3 25 | 4.5% | 11.7% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 22.1% | 19.2% | ||
| Q4 24 | -3.1% | 27.6% | ||
| Q3 24 | -2.0% | 6.0% | ||
| Q2 24 | 3.9% | 16.9% | ||
| Q1 24 | -6.7% | 21.0% |
资本支出强度HURCMLAB
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 1.0% | 1.8% | ||
| Q2 25 | 0.8% | 1.7% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.8% | 1.3% | ||
| Q3 24 | 0.5% | 3.1% | ||
| Q2 24 | 0.3% | 1.5% | ||
| Q1 24 | 1.0% | 0.9% |
现金转化率HURCMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HURC
| Computerized Machine Tools | $35.9M | 79% |
| Service Parts | $6.7M | 15% |
| Service Fees | $2.3M | 5% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
